CD49d and CD38 are independent negative prognostic markers in chronic lymphocytic leukemia (CLL). Their associated expression marks a disease subset with a highly aggressive clinical course. Here, we demonstrate a constitutive physical association between the CD49d/CD29 integrin complex and CD38 in primary CLL cells and B-cell lines by (i) cocapping, (ii) coimmunoprecipitation and (iii) cell adhesion experiments using CD49d-specific substrates (vascular-cell adhesion molecule-1 or CS-1/H89 fibronectin fragments). The role of CD38 in CD49d-mediated cell adhesion was studied in CD49d þ CD38 À cells (P ¼ 0.0006) and a more complex distribution of F-actin to the adhesion sites. Lastly, adherent CD49d þ CD38 þ cells were more resistant to serum-deprivation-induced (Po0.001) and spontaneous (P ¼ 0.03) apoptosis than the CD49d þ CD38 À counterpart. Altogether, our results point to a direct role for CD38 in enhancing CD49d-mediated adhesion processes in CLL, thus providing an explanation for the negative clinical impact exerted by these molecules when coexpressed in neoplastic cells.
INTRODUCTION
The role of microenvironment in tumor cell maintenance and expansion has been described for different B-cell malignancies, including chronic lymphocytic leukemia (CLL). CLL cells, like other small B-cell lymphoma cells, develop in specialized niches present in the bone marrow and in secondary lymphoid organs, where interactions with different populations of accessory stromal/ endothelial cells and T cells through different receptor--ligand pairs convey proliferation and survival signals to malignant cells. 1 --5 A key role in the interactions of CLL cells with other microenvironmental cell populations has been described for CD49d and CD38, two molecules whose expression by CLL cells is generally correlated, 6 --8 and is known to mark disease subsets with particularly unfavorable clinical outcomes. 6 --12 CD49d, also known as the a4 integrin subunit, is usually complexed with CD29 (the b1 subunit) and mediates interactions with extracellular matrix components, including fibronectin (FN) 13, 14 or with opposing cells through the binding with vascular-cell adhesion molecule-1 (VCAM-1). 15 CD38 is a cell surface glycoprotein acting as an enzyme and a receptor for CD31, this interaction regulating lymphocyte adhesion to endothelial cells and promoting lymphocyte activation. 16 --18 In CLL cells, CD49d and CD38 are functionally linked, through the production of specific soluble factors, in a circuitry regulating adhesion and survival of CD49d þ CD38 þ CLL. 5 Several studies demonstrated the propensity of CD38 to form supra-molecular complexes in various hematopoietic cell types. 19 --24 The reason of such physical interactions of CD38 is at least twofold. First, given the lack of signaling motifs in the cytoplasmic tail of CD38, CD38-mediated intracellular signal transduction is strongly influenced by lateral associations, usually occurring in the context of membrane lipid rafts, with other cell surface molecules and/or membrane adaptors specialized in signal transduction, for example, CD19 and CD81. 22, 25 Second, CD38, through its lateral interactions, may enhance the activity of other molecules. In particular, CD38 was demonstrated to have an active role in synergizing with the CXCR4 signaling pathway, by controlling CXCL12-driven chemotaxis/homing processes of CLL cells to growth-favorable niches. 26 Moreover, lateral associations on the plasma membrane of the CD49d/CD29 complex, with the tetraspanins CD81 and CD9, have been demonstrated to have a role in enhancing the phosphorylation cascade triggered by the integrin --ligand association. 27 Recently, a cell surface macromolecular complex which includes CD38, CD49d, CD44 and MMP-9 has been found in poor prognosis CLL. 28 Here we investigated in detail the physical relationship between the CD49d/CD29 heterodimer and CD38 in CLL, and provided evidence that the resulting molecular complex enhances CD49d-mediated activities.
MATERIALS AND METHODS

CLL patients and cell lines
This study was approved by the Internal Review Board of the Centro di Riferimento Oncologico of Aviano (Approval no. IRB-05-2010). It includes peripheral blood samples collected after informed consent for diagnostic/ prognostic purposes from 488 CLL patients diagnosed according to standard criteria, 29 and characterized for CD49d, CD38 and ZAP-70 expression, IGHV mutational status, and fluorescence in situ hybridization karyotype (Supplementary Table S1 ). 6, 30 This series was employed to extend our previous observations on correlated expression and clinical impact of CD49d and CD38 in CLL. 6, 31, 32 For CD49d and CD38 simultaneous detection, a combination of anti-CD5-FITC, anti-CD49d-PE, anti-CD19-PerCP and anti-CD38-APC monoclonal antibodies (mAbs; Becton Dickinson, San Jose, CA, USA) was used. A CLL case was judged CD49d þ and/or CD38 þ when the marker was expressed in at least 30% of the CD5 þ CD19 þ CLL cell population, as described. 6, 10 To correlate the fluorescence intensity of CD38 and CD49d, mean fluorescence intensity data were also recorded.
Functional and biochemical experiments (see below) were carried out on CLL cases expressing either a CD49d Table S2 ). In these cases, CLL cells were purified from the peripheral blood by density gradient centrifugation followed by negative selection using a mixture of anti-CD3, anti-CD16 and anti-CD14 mAbs (Laboratory of Immunogenetics, Turin, Italy) and separation by immunomagnetic beads, as described. 33 In all cases B-cell purity was X95%, as assessed by flow cytometry.
The Burkitt's lymphoma cell line Raji (CD49d þ CD38 þ ), the myelomalike cell line RPMI-8226 (CD49d þ CD38 þ ) and the CLL-derived cell line Mec-1 (Mec-1 WT; CD49d þ CD38 À ) were cultured as described. 33 CD49d
(Mec-1 SEW or Mec-1 EP) transfectants were generated by infection with lentiviral particles or electroporation of expression vectors containing or not the genetic material for CD38, as described. 26 Cocapping experiments and cell treatment with methyl-bcyclodextrin
Cocapping experiments were carried out on primary CLL cells and cell lines exactly as previously reported utilizing anti-CD38 (SUN-4B7, Laboratory of Immunogenetics), anti-CD49d (clone HP2/1, Serotec, Oxford, UK) mAbs and TRITC-labeled GaMIg (Dako, Glostrup, Denmark) for capping, and anti-CD38-FITC, CD81-FITC, HLA Class I-FITC (Laboratory of Immunogenetics), CD29-FITC (clone K20, Immunotech, Marseille, France) and CD49d-FITC (clone 44H6, Serotec) for counterstaining. 33 When indicated, CLL cells were pre-incubated (30 min, 37 1C) with 10 mM methyl-b-cyclodextrin (MbCD, Sigma, St Louis, MO, USA). Cells were fixed (4% paraformaldehyde), settled on poly-L-lysine-coated coverslips, and analyzed either with an Olympus 1 Â 70 microscope, using the FluoView software (Olympus, Milan, Italy), or with a Nikon Eclipse 90i microscope and the ND2 software (Nikon, Tokyo, Japan).
Lipid raft isolation, immunoprecipitation and western blotting
Lysates from purified CLL, Mec-1 SEW or Mec-1 S38W cells were separated into supernatant (S; cytosolic and soluble membrane proteins) and pellet (P; cholesterol-enriched membrane areas and cytoskeletal proteins) fractions in the presence or not of 60 mM octyl-D-glucopyranoside, as described. 22 Immunoprecipitations were performed with anti-CD49d (Serotec), anti-CD29 (clone Moon-4), anti-CD38 (clones OKT-10 and AT13/ 5) and X63 (irrelevant, isotype-matched mAb, all produced in the Laboratory of Immunogenetics) mAbs and analyzed by western blot using anti-CD38 (SUN-4B7), anti-CD49d (Abcam, Cambridge, UK), anti-CD29 (Moon-4) or anti-Vav-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) mAbs, as described. 22, 26 Selected western blotting was performed using cell lysates from Mec-1 incubated or not with anti-CD38 mAbs and left to adhere onto culture coverslips for 2 and 5 min, hybridized with antibodies recognizing Vav-1 (Santa Cruz), Vav-1 pTyr-174 (Abcam), and Beta actin (Sigma). Densitometric quantitation of western blots was determined with the ImageJ 1.43u software (http://rsbweb.nih.gov/ij/).
Preparation of VCAM-1-or FN-coated culture dishes/coverslips The H89 FN fragment, containing several binding sites for CD49d, was a kind gift of Angeles Garcia-Pardo (Centro de Investigaciones Bioló gicas, Madrid, Spain). Purified FN CS-1 fragments were a kind gift of Alfonso Colombatti (Centro di Riferimento Oncologico, Aviano, Italy). The human recombinant VCAM-1 was from R&D Systems (Minneapolis, MN, USA).
For adhesion assays, 96-well flat-bottomed culture dishes were coated with 10 mg/ml FN (H89 or CS-1 fragments) or VCAM-1 in bicarbonate buffer (4 1C, overnight), followed by phosphate-buffered saline supplemented with 1.0% bovine serum albumin (2 h, room temperature). For immunofluorescence studies, ethanol-washed coverslips were placed into 24-well plates and coated with either VCAM-1 or FN as described above.
Cell adhesion assay For adhesion assays with primary CLL cells, 1 Â 10 6 purified cells were seeded onto coverslips coated with the appropriate substrate for 15 min. Adherent cells were fixed (4% paraformaldehyde), and coverslips mounted on slides and microscopically analyzed using a Â 20 objective. After acquiring at least 10 fields per slide, adherent cells were counted, and results reported as mean number of adherent cells per field.
Immunofluorescence
Mec-1 (0.2 Â 10 6 /well) or primary CLL cells (1 Â 10 6 /well) were plated onto coverslips coated with the appropriate substrate and incubated for different time points at 37 1C to promote adhesion. Adherent cells were sequentially incubated with unconjugated anti-CD49d mAbs (clone 44H6, Serotec), TRITC-labeled GaMIg secondary antibody (Millipore, Billerica, MA, USA) and anti-CD38-FITC. Cells were fixed, and coverslips were mounted on slides and microscopically analyzed as above.
For Vav1 pTyr-174 detection, adherent fixed cells on coverslips were permeabilized with 0.1% Tween-20, blocked with 10% fetal bovine serum, and stained with anti-Vav-1 pTyr-174 (Abcam) followed by TRITCconjugated secondary antibody and fluorescein-labeled Phalloidin (Sigma) to visualize F-actin filaments. Coverslips were mounted on slides and microscopically analyzed as above. Staining quantification was performed using ImageJ software by acquiring at least 10 high-power fields for analysis.
Cell viability assays 
Statistical analysis
Data were compared using either the non-parametric Mann --Whitney test or the Student's t-test for independent samples. Association between CD49d and CD38 expression and time-to treatment (time from diagnosis to treatment or end of follow-up) was calculated as reported. 6 All statistical analyses were performed using the MedCalc software (MedCalc, Mariakerke, Belgium).
RESULTS
Expression of CD49d and CD38 is correlated and marks a CLL subset with very poor prognosis Expression of CD49d and CD38 was investigated by flow cytometry in the neoplastic component of 488 CLL patients (Supplementary Figure S1 ). Using the 30% positive cut-off value for both the antigens, 9 Figure S1A and B). CD38 and CD49d expression intensities, evaluated as mean fluorescence intensity, were significantly correlated (Pearson's correlation coefficient r ¼ 0.81, Po0.0001, n ¼ 75, Supplementary Figure S1C ). Moreover, the simultaneous analysis of CD49d and CD38 mean fluorescence intensity performed in the CD49d þ CD38 þ cohort used for functional experiments (Supplementary Table S2 ), demonstrated a high correlation between the molecules also at the cell level (in all cases r40.80, Po0.005, n ¼ 11, Supplementary Figure S1D ). Figure S1E ).
CD49d and CD38 are laterally associated both inside and outside lipid rafts The membrane relationship between CD49d and CD38 in CD49d þ CD38 þ CLL cells (Supplementary Table S2 ) was analyzed by cocapping experiments. Antibody-mediated cross-linking of CD49d led to its redistribution in a polar aggregate at the cell surface, where a clear colocalization of CD38 was observed ( Figure 1 ). As summarized in Table 1 , anti-CD49d mAbs induced capping in about 75% of CLL cells; of these, 80% displayed a redistribution of CD38 in the context of the capping area. Similarly, a redistribution of CD49d molecules was obtained when capping was induced by anti-CD38 mAbs ( Figure 1 ). Further cocapping experiments revealed the presence of the integrin b1 subunits (CD29) in CD49d caps, indicating that the a4 integrin subunit (CD49d) is part of the a4b1 (CD49d/CD29) heterodimer. The overlapping of CD81 staining in CD49d caps confirmed the association between this tetraspanin with a4 integrins, 27 whereas the lack of redistribution of HLA Class I molecules when caps were induced by anti-CD49d mAbs, indicated the specificity in the molecular associations revealed by this technique (Figure 1) .
Association between CD49d and CD38 was also confirmed in CD49d þ CD38 þ B-cell lines (Raji and RPMI-8226; Supplementary Figure S2A) . In both the cell lines, cocaps of CD38 scored 60% of CD49d-induced caps, and CD49d molecules were observed in 70% of caps induced by anti-CD38 mAbs. Also in these cellular models, CD49d was laterally associated with CD29 and CD81 but not with HLA-I molecules (Table1 and Supplementary Figure S2B) .
The lateral association between CD49d and CD38 was next confirmed in primary CLL cells (n ¼ 6) at the biochemical level by immunoprecipitation of CD49d followed by western blotting with anti-CD38 mAb. These experiments were performed after separating cell membranes on the basis of cholesterol content, into S and P fractions. 22 This approach demonstrated that CD38 coimmunoprecipitated with CD49d, and that CD49d/CD38 complexes could be found both inside and outside the cholesterolenriched raft domains. Although no preferential association was observed when anti-CD38 immunoprecipitates were blotted with anti-CD49d mAbs (data not shown), CD38 immunoprecipitates contained significant amounts of CD29, and CD29 immunoprecipitates were associated with both CD38 and CD49d (Figure 2a) . Collectively, these results suggest that the association between CD49d and CD38 mainly occurred via the CD29 subunit.
The maintenance of CD49d/CD38 and CD38/CD29 complexes, and their partial redistribution to the S fraction upon treatment of the cells with octyl-D-glucopyranoside (Figure 2a) , which solubilizes raft-associated proteins, suggest that these molecular interactions are independent of the integrity of lipid rafts, in line with the participation of cytoskeletal proteins stabilizing the association. A further confirmation of these observations was provided by cocapping experiments upon pretreatment of CLL cells with MbCD, a chemical that disrupts lipid rafts by extracting cholesterol from plasma membranes. Results clearly showed that the CD49d/CD38 association was largely unaffected by lipid rafts disruption; the same was observed for other associations, including CD49d/CD29, CD49d/CD81 and CD38/CD29 (Table 1 , Figure 2b and data not shown).
CD38 localizes in CD49d-specific adhesion sites The molecular interaction between CD49d and CD38 may be of functional relevance in the context of CD49d-mediated activities. To test this hypothesis, CLL cells were allowed to adhere to CD49d-specific substrates (VCAM-1 or H89/CS-1 FN fragments), and double stained with mAbs against CD49d and CD38. Confocal microscopy clearly showed a colocalization of CD49d and CD38 in the cell uropods during the stages of cell spreading onto both VCAM-1 and CS-1/H89 FN fragments (Figure 3 ). Figure S3A and data not shown), and membrane localization of CD38 was similar to that observed in primary CLL cells, being distributed both inside and outside the lipid rafts (Supplementary Figure S3B) . Cocapping experiments confirmed the CD49d/CD38 physical association also in Mec-1 S38W cells (Supplementary Figure S3C) . The preferential association between CD38 and the CD49d/CD29 complex was confirmed by showing that CD38 is present in CD49d immunoprecipitates. In line with data obtained in CLL cells, also in Mec-1 transfectants CD38 immunoprecipitates contained CD29, in turn complexed with CD49d (Supplementary Figure S3D) .
The adhesive properties of Mec-1 transfectants were investigated by adhesion experiments onto VCAM-1 substrates. A marked increase in the number of Mec-1 S38W cells adherent to VCAM-1 as compared with both Mec-1 SEW (Figures 4a and b) and Mec-1 WT (Supplementary Figure S3E) Figure S3E) in which CD38-expressing vectors were introduced by electroporation (Supplementary Figure S3E) .
Besides an increased adhesion (Figures 4a and b) , phasecontrast microscopy images highlighted a different cell morphology characterizing VCAM-1 adherent Mec-1 S38W cells. As shown in Figure 4a (lower panels), Mec-1 S38W cells displayed a more complex pattern of filopodia-like protrusions than Mec-1 SEW, with a colocalization of CD49d and CD38 in these adhesion sites.
Pre-incubation of Mec-1 S38W with the anti-CD38 mAb SUN-4B7 resulted in a significant reduction of cell adhesion onto VCAM-1, whereas no alteration was observed when using the isotype-matched anti-CD38 mAb OKT-10 (Figures 4c and d) . Moreover, Mec-1 S38W adherent cells pre-treated with the anti-CD38 mAb SUN-4B7 lost their complex pattern of cell morphology, being instead characterized by a cell shape comparable to that of Mec-1 SEW (Figure 4c, lower panels) .
Similar results, both in terms of increased adhesion and modified cell morphology of adherent cells, were obtained using FN, either as H89 or CS-1 fragments, as alternative CD49d-dependent substrate (data not shown). Collectively, these data indicate a contribution of CD38 in enhancing CD49d-mediated adhesion and cell spreading.
CD38 promotes different patterns of CD49d-mediated signaling protein phosphorylation Phosphorylation of Vav-1 at tyrosine-174 (Vav-1 pTyr-174), an early event in the downstream pathway leading to integrin-induced actin polymerization, 34, 35 was investigated in the early phases of adhesion of Mec-1 cells to CD49d-specific substrates.
After 5 min of VCAM-1 adhesion, Mec-1 S38W cells exhibited stronger phosphorylation of Vav-1 compared with Mec-1 SEW (Po0.001), mainly localized to the periphery of the cells, near the actin-rich structures (Figures 5a and b) . Consistently, western blot analysis demonstrated that adhesion onto VCAM-1 substrates for 2 and 5 min yielded a stronger upregulation of Vav-1 pTyr-174 in Mec-1 S38W than Mec-1 SEW cells (Figure 5c ), both the cell lines displaying comparable levels of total Vav-1 (data not shown). Moreover, slightly higher constitutive levels of Vav-1 pTyr-174 were observed in Mec-1 S38W (P ¼ 0.02), suggesting a basal activation of the integrin signaling pathway in CD38-expressing cells. Overlapping results were obtained in experiments carried out by utilizing other CD49d-specific adhesive substrates (that is, CS-1 or H89 FN fragments; data not shown). To test whether CD38 could be directly responsible for the recruitment of Vav-1 molecules in close contact with CD49d and the integrin signaling machinery, we immunoprecipitated Mec-1 S38W cell lysates with antibodies against CD38 or CD49d. Vav-1 was present in the CD38-immunoprecipitates both inside and outside the lipid rafts, but not in immunoprecipitates formed with anti-CD49d antibodies (Figure 5d ).
We next checked whether the reduction in cell adhesion observed after pretreatment of Mec-1 S38W with the anti-CD38 mAb SUN-4B7 could be explained by a reduction of Vav-1 activation. For this purpose, cells were pre-incubated with SUN-4B7 or with control OKT-10 anti-CD38 mAbs and left to adhere onto VCAM-1 substrates. Results revealed a significant reduction in Vav-1 phosphorylation levels in cells pre-treated with the SUN-4B7 blocking mAb, compared with the ones incubated with the control binding mAb. The effect was apparent both after 2 (P ¼ 0.01) and 5 min (P ¼ 0.001; Figure 5e ).
CD49d engagement prevents cell apoptosis triggered by serum deprivation The final issue concerned the functional effects determined by the CD38/CD49d/CD29 axis in CLL cell homeostasis. We first noticed that the growth curves of Mec-1 SEW and Mec-1 S38W overlapped in the presence of 10% fetal bovine serum or under serum deprivation, the latter a condition that blocked cell growth and dramatically affected viability starting from 3 --4 days of culture (Figure 5f ). 36 Culture of Mec-1 SEW and Mec-1 S38W on VCAM-1-coated wells exerted protective effects from cell apoptosis after 4 and 5 days of culture in serum-free conditions (Figure 5f ). whereas CLL cells from CD49d þ CD38 À cases maintained an almost uniform round shape, even in the adherent component (Figures 6b and c) .
The higher adhesive properties characterizing CD49d þ CD38 þ CLL cells were paralleled by a more activated integrin signaling pathway, as witnessed by a significantly higher degree of Vav-1 phosphorylation signals in CD49d þ CD38 þ compared with CD49d þ CD38 À CLL cells (P ¼ 0.0006), the signal being mainly distributed at the cell adhesion sites (Figures 6c and d) .
In line with the results obtained in the Mec-1 model, we checked whether CD38 expression impacted on the amount of protection from spontaneous apoptosis known to be induced by CD49d engagement by the VCAM-1 substrate. 5 Purified CLL cells from five CD49d þ CD38 À and five CD49d þ CD38 þ cases (Supplementary Table S2 ) were cultured on VCAM-1, and cell viability determined at day 7. As expected, CD49d/VCAM-1 interaction protected from spontaneous apoptosis both CD49d þ CD38 þ (P ¼ 0.004) and CD49d þ CD38 À (P ¼ 0.001) CLL cells (data not shown). However, the viability of CD49d þ CD38 þ subgroup after VCAM-1 cultures was significantly higher than that of CD49d þ CD38 À subgroup (P ¼ 0.03, Figure 6e ), in line with the notion of a functional synergy between these molecules.
DISCUSSION
Clinically, the combined analysis of CD49d and CD38 expression in CLL was demonstrated to worsen the negative prognostic information provided by any of the factors alone (see also this study), thus supporting the idea of a functional cooperation between these molecules usually coexpressed in CLL cell membranes. 6 --10,28,37 In this regard, we have previously described a pro-survival circuitry operating in the context of CD49d þ CD38 þ CLL bone marrow milieu, sequentially involving the CD38/CD31 pair, CCL3 and CCL4 with their receptors, and eventually pro-survival signals delivered through the CD49d/VCAM-1 axis. 5 Moreover, CD49d and CD38 have been linked together in a recent study demonstrating that coculture of CLL cells with endothelial cells determines a significant increase of CD49d and CD38 expression, and enhances CLL cell viability, these effects being mediated by activation of the NF-kB transcription factor Rel A. 38 The starting observation of the present study was that CD49d and CD38 along with CD44 and MMP-9 are physically associated on the membrane of CLL cells as part of a macromolecular complex. 28 Moving from these observations, here we investigated in detail the relationship between CD38 and the CD49d/CD29 integrin by: (i) cocapping experiments, a validated experimental procedure for disclosing membrane molecular complexes, 33 demonstrating a colocalization of CD38 in polar aggregates containing CD49d molecules; (ii) bidirectional immunoprecipitation experiments, providing evidence for an association between CD38 and the CD49d/CD29 integrin heterodimer, both inside and outside the cell membrane lipid rafts. The last finding suggests that the CD49d/CD29/CD38 complexes are free to shuttle in and out of these specialized cholesterol-enriched membrane microdomains, where signaling transduction is organized. 22, 39 At variance with what observed for CD38/CD19 association, 22 CD49d/ CD29/CD38 complexes were not dependent on integrity of the membrane structure, as the association was unaffected by cholesterol depletion. It is therefore likely that these molecules are joined together by other cellular structures, including cytoskeletal proteins, known to directly or indirectly associate with integrins. 40 Once bound by specific ligands, integrins deliver outside-in signals that control cell proliferation, survival, gene induction, differentiation and cell motility. To achieve these diverse biological outcomes, integrins are recruited into complexes containing numerous cytoskeletal proteins and signaling molecules that can determine conformational changes leading to higher affinity forms of the integrin itself. 40, 41 In addition, ligandbinding avidity can be increased by lateral associations with other transmembrane molecules (for example, the tetraspanin CD81), independently of ligand engagement. 42 In this context, the presence of CD38 at sites of CD49d binding to its natural ligands may represent an intriguing suggestion for a functional role of CD38 in the adhesion processes mediated by CD49d. The strategy used to test this working hypothesis was to challenge CD49d þ CD38 þ and CD49d þ CD38 À cells in comparative adhesion assays, using transfectants from the CLL-derived cell line Mec-1, as well as primary CLL samples. The results from these experiments indicate that: (i) CD49d þ CD38 þ cells had higher propensity to adhere to CD49d-specific substrates (either VCAM-1 or FN) compared to CD49d þ CD38 À cells; (ii) adherent CD49d þ CD38 þ cells displayed a distinctive morphology, characterized by a more complex pattern of filopodia-like protrusions compared with cells expressing a CD49d þ CD38 À phenotype. Both the phenomena were reverted by pre-exposure of cells to selected anti-CD38 mAbs, suggesting that mAb binding to specific domains of CD38 would reduce the accessibility of the CD49d/ CD29 heterodimer to its ligands or, more intriguingly, CD38 blocking might affect CD49d conformational changes. Notably, the anti-CD38 mAb that was effective in hampering CD49d-mediated adhesion was also capable to inhibit migration of CLL cells induced by CXCL12 through its receptor CXCR4, another surface structure operating in close contact with CD38. 26 The more efficient adhesive properties characterizing CD49d þ CD38 þ CLL cells could be explained on the basis of a cooperation between the two molecules. In particular, we hypothesized that a possible role of CD38 in CD49d-mediated adhesion could be the recruitment of proteins involved in the downstream integrin signaling leading to actin polymerization and cell adhesion. In this context, attention was focused on Vav-1, a key molecule that operates as guanine exchange factor for Rac and Cdc42, two Rho GTPases involved in lamellipodia/filopodia generation in various cell models. 34, 35, 43 Upon integrin engagement, Vav-1 can become phosphorylated on tyrosine-174, as part of an intracellular signaling cascade leading to adhesion and cytoskeleton rearrangement. The higher levels of Vav-1 phosphorylation upon adhesion onto CD49d-specific substrates, described in Mec-1 S38W and in primary CD49d þ CD38 þ CLL cells, can be the result of a more robust integrin signaling pathway characterizing CD49d þ CD38 þ cells. In this regard, CD38 could contribute by increasing the recruitment of either key signaling molecules responsible for Vav-1 phosphorylation, 34, 44 or of Vav-1 itself. To corroborate the latter hypothesis, the presence of Vav-1 was demonstrated in the Mec-1 S38W cell lysates immunoprecipitated with anti-CD38, but not in immunoprecipitates of the same cells formed with anti-CD49d antibodies. Moreover, pre-exposure of Mec-1 S38W cells with the same anti-CD38 mAbs affecting cell adhesion, resulted in a significant reduction of Vav-1 phosphorylation. This finding indicates that CD38 can operate by recruiting Vav-1 in close contact to the CD49d/CD29 complexes, potentiating its phosphorylation and the activation of the integrin signaling pathway. Notably, a similar association between CD38 and Vav-1 has been reported to promote cell growth and differentiation in a human myeloblastic leukemia cell model. 45 Microenvironmental interactions in bone marrow and secondary lymphoid organs confer growth advantages and extend CLL cell survival. For these reasons they are deemed to be critical in disease progression and resistance to therapy. 1, 46 The CD49d/ VCAM-1/FN axes regulate recirculation of leukemic cells from the bloodstream to bone marrow and lymphoid organs, deliver prosurvival signals and promote resistance to drug-induced apoptosis. 5, 11, 47 In the present study, a more marked anti-apoptotic effect was exerted upon CD49d/VCAM-1 interactions in CD49d þ CD38 þ cells, as compared with CD49d þ CD38 À cells. This observation can be explained by a more efficient adhesion of CD49d þ CD38 þ cells, and a consequent more pronounced activation of the anti-apoptotic machinery, 5,11 also thanks to the contribution to the survival process of specific signaling proteins, including Vav-1, 48 already recruited to the adhesion site. Although further studies are needed to fully disclose the mechanism(s) behind the role of CD38 in CD49d-mediated adhesion in CLL, the present work provides evidence of a functional interaction between these molecules, which could explain at least in part the negative clinical outcome characterizing patients with a CD49d þ CD38 þ CLL clone. This finding may also have a therapeutic relevance by envisioning the combined use of anti-CD49d and anti-CD38 mAbs, as well as of bi-specific antibodies simultaneously recognizing CD49d or the CD49d/CD29 heterodimer and CD38, to target the neoplastic component of this poor prognosis CLL subset.
